Literature DB >> 26442803

Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy.

Rachel C Lynn1, Daniel J Powell1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26442803      PMCID： PMC4817918          DOI： 10.1038/mt.2015.162

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  20 in total

1.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.

Authors:  Dhanalakshmi Chinnasamy; Zhiya Yu; Marc R Theoret; Yangbing Zhao; Rajeev K Shrimali; Richard A Morgan; Steven A Feldman; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

Review 3.  Up on the tightrope: natural killer cell activation and inhibition.

Authors:  Lewis L Lanier
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

4.  T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.

Authors:  Heather VanSeggelen; Joanne A Hammill; Anna Dvorkin-Gheva; Daniela G M Tantalo; Jacek M Kwiecien; Galina F Denisova; Brian Rabinovich; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2015-06-30       Impact factor: 11.454

5.  Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.

Authors:  Tong Zhang; Amorette Barber; Charles L Sentman
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

6.  Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.

Authors:  Tong Zhang; Bethany A Lemoi; Charles L Sentman
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

7.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Authors:  G Gross; T Waks; Z Eshhar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

8.  Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.

Authors:  Amorette Barber; Charles L Sentman
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

Review 9.  NKG2D ligands in tumor immunity.

Authors:  N Nausch; A Cerwenka
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

10.  Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.

Authors:  Amorette Barber; Agnieszka Rynda; Charles L Sentman
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422
View more
  7 in total

1.  Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

Authors:  Jenessa B Smith; Evripidis Lanitis; Denarda Dangaj; Elizabeth Buza; Mathilde Poussin; Caitlin Stashwick; Nathalie Scholler; Daniel J Powell
Journal:  Mol Ther       Date:  2016-07-21       Impact factor: 11.454

2.  Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.

Authors:  Lin Xiao; Dongzhi Cen; Haining Gan; Yan Sun; Nanqi Huang; Hanzhen Xiong; Qiongmei Jin; Liqun Su; Xuejuan Liu; Kejian Wang; Guangrong Yan; Tianfa Dong; Shangbiao Wu; Pengzhi Zhou; Jinshan Zhang; Weixiang Liang; Junlan Ren; Yaoshu Teng; Can Chen; Xue Hu Xu
Journal:  Mol Ther       Date:  2019-03-20       Impact factor: 11.454

Review 3.  Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy.

Authors:  Kushal Prajapati; Cynthia Perez; Lourdes Beatriz Plaza Rojas; Brianna Burke; Jose A Guevara-Patino
Journal:  Cell Mol Immunol       Date:  2018-02-05       Impact factor: 11.530

4.  Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.

Authors:  Yali Han; Wei Xie; De-Gang Song; Daniel J Powell
Journal:  J Hematol Oncol       Date:  2018-07-06       Impact factor: 17.388

5.  NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.

Authors:  Alejandra Leivas; Antonio Valeri; Laura Córdoba; Almudena García-Ortiz; Alejandra Ortiz; Laura Sánchez-Vega; Osvaldo Graña-Castro; Lucía Fernández; Gonzalo Carreño-Tarragona; Manuel Pérez; Diego Megías; María Liz Paciello; Jose Sánchez-Pina; Antonio Pérez-Martínez; Dean A Lee; Daniel J Powell; Paula Río; Joaquín Martínez-López
Journal:  Blood Cancer J       Date:  2021-08-14       Impact factor: 11.037

Review 6.  Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.

Authors:  J Obajdin; D M Davies; J Maher
Journal:  Clin Exp Immunol       Date:  2020-07-25       Impact factor: 4.330

7.  Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts.

Authors:  Wei Xia Ang; Yu Yang Ng; Lin Xiao; Can Chen; Zhendong Li; Zhixia Chi; Johan Chin-Kang Tay; Wee Kiat Tan; Jieming Zeng; Han Chong Toh; Shu Wang
Journal:  Mol Ther Oncolytics       Date:  2020-05-04       Impact factor: 7.200
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.